Florida Attorney General James Uthmeier filed a lawsuit Tuesday against the Planned Parenthood abortion business for lying about abortion pills and falsely claiming they’re safe.
The lawsuit accuses Planned Parenthood of deceptive marketing practices in promoting chemical abortion pills, alleging the organization misled women by downplaying the risks of severe complications.
The suit, filed in state court, claims Planned Parenthood violated Florida’s Deceptive and Unfair Trade Practices Act by distributing materials that falsely portrayed the abortion pills as safe and effective without adequately disclosing potential dangers. Uthmeier’s office said the allegations stem from an investigation revealing that Planned Parenthood’s promotional content omitted critical information about adverse events, including hemorrhage, infection and the need for emergency interventions.
REACH PRO-LIFE PEOPLE WORLDWIDE! Advertise with LifeNews to reach hundreds of thousands of pro-life readers every week. Contact us today.
“It is vile that Planned Parenthood cares more about lining their pockets than providing women with factual information about the health risks of chemical abortion drugs,” said Attorney General James Uthmeier. “When it comes to health and safety in Florida, we won’t tolerate blatant lies using fabricated medical ‘facts’ that have no scientific basis.”
Uthmeier’s lawsuit seeks injunctive relief to halt the deceptive practices, civil penalties and restitution for affected women.
The action highlights growing scrutiny of chemical abortions, which account for more than half of all abortions nationwide. Pro-life advocates have long argued that relaxed federal regulations since 2016 — including extending the gestational limit for use from seven to 10 weeks and eliminating in-person dispensing requirements — have endangered women’s health by prioritizing access over safety.
A recent analysis by the Ethics & Public Policy Center, a conservative think tank, examined over 865,000 insurance claims from women who took abortion pills and found that 10.93% — or 94,605 cases — involved serious adverse events serious enough to require medical attention. Those complications included bleeding, discharge, pain or anxiety prompting emergency room visits, according to the study.
The findings, drawn from verified insurance records, contrast sharply with abortion industry reports that have described complications as “extremely rare” or the pills as “safer than Tylenol.”
The EPPC data prompted a federal response, with Health and Human Services Secretary Robert F. Kennedy, Jr., and FDA Commissioner Marty Makary announcing a new government assessment of the drug’s safety and efficacy.
Supporting studies cited in the EPPC analysis include a 2009 Finnish review of over 42,000 patients showing a 20% adverse event rate, with 15.6% experiencing hemorrhage; a 2023 Canadian study of nearly 40,000 cases finding 10.3% emergency department visits; and a 2015 California examination revealing more than 5% of users facing incomplete abortions, infections or surgical injuries.
